Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | OTC | P00480 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | GNPAT | O15228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93364 | 1.00 | C3AR1 (0.47) | C3AR1CTDSP1FOLH1SHMT1MEN1 | |
| SCHEMBL30404095 | 1.00 | C3AR1 (0.47) | C3AR1CTDSP1FOLH1SHMT1MEN1 | |
| SCHEMBL25356845 | 0.95 | FOLH1 (0.45) | C3AR1CTDSP1FOLH1NOD1 | |
| SCHEMBL93490 | 0.95 | FOLH1 (0.45) | C3AR1CTDSP1FOLH1NOD1 | |
| SCHEMBL17769024 | 0.86 | FOLH1 (0.38) | C3AR1FOLH1MEN1KMT2AGAA | |
| SCHEMBL27844592 | 0.86 | C3AR1 (0.39) | C3AR1CTDSP1FOLH1SHMT1MEN1 | |
| SCHEMBL93473 | 0.86 | FOLH1 (0.38) | C3AR1FOLH1MEN1KMT2AGAA | |
| SCHEMBL1504531 | 0.86 | FOLH1 (0.38) | C3AR1CTDSP1FOLH1MEN1KMT2A | |
| SCHEMBL5554963 | 0.86 | C3AR1 (0.39) | C3AR1CTDSP1FOLH1SHMT1MEN1 | |
| SCHEMBL162756 | 0.86 | FOLH1 (0.38) | C3AR1FOLH1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-11897963-B2 | Anti-Jagged1 antigen binding proteins | AMGEN INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20110135657-A1 | HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF | AMGEN INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110045587-A1 | TOXIN PEPTIDE THERAPEUTIC AGENTS | AMEGEN INC. | 2011-02-24 | — | — | US | disclosed |
| US-20100323954-A1 | CHIMERIC POLYPEPTIDES AND USES THEREOF | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010148142-A1 | CHIMERIC FGF19 POLYPEPTIDES AND USES THEREOF | AMGEN INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-7833979-B2 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | AMGEN INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010042747-A2 | FGF21 MUTANTS AND USES THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-1940452-A2 | CGRP PEPTIDE ANTAGONISTS AND CONJUGATES | Amgen, Inc (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070269369-A1 | Modified Fc molecules | AMGEN INC. | 2007-11-22 | — | — | US | disclosed |
| WO-2007048026-A2 | CGRP PEPTIDE ANTAGONISTS AND CONJUGATES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405157-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | MC3R, MC1R, MC4R | C3AR1 994/4885CTDSP1 4368/4885FOLH1 212/4885 |
| US-20070071764-A1 | conjugated polymer drug contains toxin protein and polyethylene glycol; treating autoimmune diseases, such as multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, dermatitis, rheumatoid arthritis, psoriasis; asthma, allergy, restinosis, fibrosis, scleroderma, glomerulonephritis | F11, F13A1, F12 | C3AR1 98/4885CTDSP1 892/4885FOLH1 1479/4885 |
| US-20110045587-A1 | TOXIN PEPTIDE THERAPEUTIC AGENTS | F13A1, ANTXR2, F13B | C3AR1 132/4885CTDSP1 1209/4885FOLH1 944/4885 |
| US-20070269369-A1 | Modified Fc molecules | FCGR1A, FCGRT, FCGR2A | C3AR1 23/4885CTDSP1 155/4885FOLH1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.